Ixico Share Discussion Threads

[mad foetus] 20/4/2020 08:02

I've added a little. Happy with those results and expect this to be a real long term winner

[cheshire man] 14/4/2020 14:11

Chart say's it all really,,,,,:-)

[cheshire man] 14/4/2020 06:46

"IXICO expects to report revenue growth for the six months ended 31 March 2020 of at least 25% compared to the corresponding period in the previous financial year . The Company finished the half year with GBP6.7m of cash and no debt."

[rathean] 14/4/2020 06:26

Excellent contract win tempered by withdrawal of guidance and acknowledgement that clinical trials are being impacted by c19.

[deltaham] 19/3/2020 12:06

“IXICO PLC's (LON:IXI) chief business officer Lammert Albers talks Proactive's Andrew Scott through an extended contract they've secured with Vaccinex Inc (NASDAQ:VCNX).” IMHO a very upbeat interview.

[jpuff] 16/3/2020 13:59

IXICO plc IXICO announces expanded contract with VaccinexSource: RNS Non-RegulatoryTIDMIXIIXICO plc16 March 202016 March 2020IXICO plc("IXICO" or the "Company")IXICO announces an expanded contract for its imaging services with VaccinexSupports Vaccinex's diversification into clinical development of pepinemab for Alzheimer's diseaseIXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces an award of a contract to provide imaging services for Vaccinex Inc.'s (Nasdaq: VCNX) planned Phase Ib/IIa trial of pepinemab, a potential treatment of Alzheimer's disease (AD). This will build on the Company's existing contract to support Vaccinex's Phase II study of pepinemab in the Huntington's disease SIGNAL trial, which was previously announced in September 2017.Giulio Cerroni, Chief Executive Officer of IXICO, commented:"This AD trial, called SIGNAL - AD, is part of a new wave of investment in treatments for neurodegeneration by the global biopharmaceutical industry, with additional assets being brought through the pipeline thanks to the insights unlocked in earlier research programmes."We are delighted that Vaccinex has chosen to expand our partnership to support its diversification into Alzheimer's disease. Our existing project with Vaccinex, the SIGNAL trial, is in Huntington's disease (HD) to study the safety and efficacy of pepinemab, where the positive imaging results obtained in an interim cohort analysis indicated its potential in additional therapeutic areas; this contract was initiated in 2017 and the new award is a great testament to the achievements of our two organisations working diligently together since then. We are pleased to be part of Vaccinex's effort to bring hope to AD patients and their families."This contract does not have significant impact on management's expectations of perfomance for the year.For further information please contact: IXICO plc [phone] Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer Optimum Strategic Communications [phone] Mary Clark, Supriya Mathur, Manel Mateus [e-mail] About IXICOIXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience.Our goal is to be a leading proponent in the use of AI in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.More information is available on www.IXICO.comAbout Vaccinex, Inc.Vaccinex, Inc. is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, with currently active clinical trials in non-small cell lung cancer and Huntington's disease. Vaccinex is based in Rochester, New York.This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.ENDNRABSGDXIXBDGGX(END) Dow Jones NewswiresMarch 16, 2020 05:00 ET (09:00 GMT)

[johndoe23] 27/2/2020 11:43

I sold at 88p last month, thinking 60-65p might be a good in. Not now!!

[hpcg] 27/2/2020 11:37

Agree, 48, 35 and then back to the mid 20s level. Mind by that time the market cap would be just twice cash.

[johndoe23] 27/2/2020 11:31

Support at 59-60p broken. Next support 48p i can see

[hpcg] 26/2/2020 17:01

otemple3 - same here. The only rationality I can see for the price drop is if one expects covid-19 to increase morbidity for those with brain diseases to such an extent that their research becomes pointless I would anticipate literally no economic malus from the virus whatsoever.

[otemple3] 26/2/2020 16:09

Added today at 62p & 64p as looks excellent value with strong top and bottom line growth coupled with c.25% of mrk cap in cash

[cheshire man] 19/2/2020 17:17

Good to see the chart rebound today :-)

[halfpenny] 19/2/2020 13:32

IXI should have some great contract news flow. Great technology in high demand. IP is a positive asset to have and its creating more value with every software release. The big companies may even go for a takeover at these cheap prices with a strong IP value. Interesting times ahead.

[wfcreserves] 18/2/2020 12:56

AGM was on 17th January?

[halfpenny] 18/2/2020 07:44

WOW overshoot provides a great opportunity but i expect MM’s to take advantage before market opens. IXI provide a great opportunity at these prices. Software maintains value with the IP being a great asset. AI and the medical space is a must to tuck away. So pleased to get shares at these prices today. History shows it will sharply move up in the short term. Keep on smiling.. AGM was yesterday so i wait for the update shoukd be positive.

[hpcg] 17/2/2020 23:14

In my opinion, which could be proven wrong by future events, Thompson is making a value investor error. Viz, that the share price can't go up as it is now really expensive, so best sell. This neglects that some companies grow. To name one example, I'm not sure that Salesforce has ever traded below a PE of 50, and has sometimes been in three figures, but its share price has gone from $18 to over $180 in 10 years, and from $3.5 in 15 years. CRM first made an operating profit in 2016!

There are UK listed companies such as FDEV and FEVR that have had more rapid rises and substantially higher PEs. In reality the price / earnings ratio is just about the -least significant ratio there is.

[jondev] 17/2/2020 23:10

I didn't sell today - when I heard the advice was to take profits I did think about it for a few mins but instead I had a little top up. It seems quite a few people still have an appetite for this one.

[molatovkid] 17/2/2020 21:34

He should have said 'take profits - quickly'

[hiraniha] 17/2/2020 19:58

The irony is the 'take profits' recommendation has resulted in the price falling back to where ST was tipping it as a buy a few months ago.

[halfpenny] 17/2/2020 17:27

Wiw IXI provide a great opportunity at these prices. Software maintains value with the IP being a great asset. AI and the medical space is a must to tuck away. So pleased to get shares at these prices today. History shows it will sharply move up in the short term. Keep on smiling.. AGM was today so i wait for the update shoukd be positive.

[melody9999] 17/2/2020 16:32

If you are not already holding, today is certainly a buying opportunity at this price.

[martinthebrave] 17/2/2020 15:45

Simon Thompson 12th December 2019 - "BUY"

Annual results from Aim-traded IXICO (IXI:68p), a London-based company that uses proprietary artificial intelligence (AI) software algorithms to analyse images from brain scans were materially better than I had anticipated when I recommended buying the shares, at 33p, in the summer ('Alpha Report: Simon Thompson spies opportunity in cutting edge technology', 23 July 2019). Having upgraded his earnings forecasts twice since then, analyst Chris Donnellan at house broker Cenkos Securities has done so again on the back of the latest results, highlighting the ongoing strong momentum in the business.
The scans – magnetic resonance imaging (MRI) and positron emission tomography (PET) – provide measurements of small changes in brain structure, assess the efficacy of new drugs being trialled, monitor patient safety, and provide valuable insights on different aspects of trial performance. Outsourcing the work to clinical research organisations is proving popular with the world’s largest biopharmaceutical companies that are investing huge sums of money in the field of neurology to target therapies for diseases affecting the central nervous system including Huntington’s, Alzheimer’s and Parkinson’s disease.
IXICO reported record annual revenue of £7.6m, up 40 per cent year-on-year, and it’s high value work as gross margins were 6.6 percentage points higher at 65.4 per cent. This meant that gross profit, up 55 per cent to £5m, increased at a faster rate than revenue. So, with a relatively fixed cost base – operating expenses only increased by 14 per cent – IXICO has passed the inflexion point whereby an increasing proportion of gross margin earned from incremental revenue is converted into profit. To put the operational gearing of the business into perspective, IXICO’s operating loss of £0.8m on revenue of £5.4m in 2018 turned into an operating profit of £364,000 on revenue of £7.6m in the 12 months to 30 September 2019. Cenkos had predicted a maiden operating profit of £50,000, so this was a major earnings beat.
Moreover, because gross margins are higher than Cenkos had anticipated, and operating costs lower, the broking firm has been forced to upgrade its operating profit estimates by a thumping 70 per cent to £508,000 for the 2019/20 financial year, and by 10 per cent to £1.04m the year after. Forecasts are based on annual revenue rising by 20 per cent to £9m and £10.8m, respectively. However, even the upgraded estimates could prove conservative given that IXICO has increased revenue at a compound annual growth rate of 35 per cent over the past three financial years and continues to win new contracts ('Profiting from artificial intelligence', 28 October 2019).
Indeed, the closing order book of £15.9m equates to 80 per cent of the combined revenue forecast for the next two financial years, thus providing a high level of visibility and materially de-risking earnings estimates. IXICO has announced five notable contract wins since August, all of which highlight the value of its core technology and ability to unlock insights on a broad range of neurological disorders and across the full spectrum of clinical development.
Interestingly, one of the contracts is focused on a progressive supranuclear palsy (PSP) programme for a new client, ahead of patient enrolment. The 12-month contract, worth £400,000, is expected to lead to a larger programme of work in early 2020, highlighting how the expansion of its services into new therapeutic markets. Another new contract involves a study with an existing client that will see IXICO’s AI technology extended and deployed to several sites in mainland China.
Importantly, the company is well funded to maintain its growth trajectory, ending the 2019 financial year with net funds of £7.26m (15.5p a share), a sum equating to 25 per cent of IXICO’s market capitalisation of £31.2m. Strip out net funds, and the company’s enterprise value of £24m equates to 25 times net profit estimates of £947,000 for the 2020/21 financial year. However, if as seems likely IXICO continues to win new contracts, then analysts will be forced again to push through yet more earnings upgrades so that multiple is likely to drop sharply in due course. Buy.

We then have no material news for 2 months....

Today Simon says:

Aim-traded IXICO (IXI:85p), a London-based company that uses proprietary artificial intelligence (AI) software algorithms to analyse images from brain scans, has delivered a 157 per cent share price gain since I spotted its potential last summer ('Alpha Company Research: Simon Thompson spies opportunity in cutting edge technology', 23 July 2019). The share price is up 25 per cent since my last article (‘Playing an earnings upgrade cycle’, 12 December 2019), buoyed by news of a £1.8m extension to a Phase III study in Huntington's Disease, and a £0.6m extension to a study programme in Progressive Supranuclear Palsy.
I really like the company and feel that if IXICO continues to win new contracts then analysts will be forced again to push through more earnings upgrades given the operational leverage of the business. However, as it stands right now, the shares trade on 32 times cash adjusted net profit estimates for the 2020/21 financial year and have hit my 85p target price. Take profits.

Back to 68p - the same price as his "BUY" Tip last December.

Surely he will shortly tell us what a Bargain it is again....

[hpcg] 17/2/2020 15:38

Toffeeman - a fart in a paper bag can move a 40 million market cap stock. Similar moves to today are visible in this chart. For sure Simon Thompson in particular influences prices, but plenty of other commentators do too. It is still a punt because it is difficult for that not to be the case in a micro cap, but at least it is not a jam tomorrow no revenue share.